Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Controversies in the Treatment of Ischemia-Reperfusion Injury, ” will focus on past and current strategies for reducing the myocardial damage caused by IRI following percutaneous coronary intervention ...

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in ...

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success with two ...